DAXOR COMPLETES NIH FUNDED I-CORPS PROGRAM FOR COMMERCIALIZATION OF CLINICAL DECISION SUPPORT SOFTWARE
July 18, 2022 08:00 ET
|
Daxor Corporation
Company Received Funding from NIH to Accelerate New Clinical Decision Support Software For Use With Daxor’s Blood Volume Analyzer for Heart Failure Treatment Oak Ridge, TN, July 18, 2022 (GLOBE...
DAXOR ANNOUNCES COOPERATIVE RESEARCH AND DEVELOPMENT PHASE II AGREEMENT WITH THE UNIFORMED ARMED SERVICES UNIVERSITY FOR THE DEVELOPMENT OF A NON-NUCLEAR BLOOD VOLUME ANALYSIS (BVA) DEVICE
June 27, 2022 08:00 ET
|
Daxor Corporation
New BVA Device Aims to Possess Gold Standard Accuracy and Reproducibility with Increased Safety, Access, Ease of Use, and Frequency of Testing Afforded by a Non-Nuclear Tracer Oak Ridge, TN, June ...
Daxor Corporation to Showcase the Benefits of BVA-100® Guided-Care at the American Association of Heart Failure Nurses (AAHFN) 18th Annual Meeting
June 13, 2022 08:00 ET
|
Daxor Corporation
Oak Ridge, TN, June 13, 2022 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, announces today it will exhibit at the American...
Daxor’s Blood Volume Analyzer (BVA-100®) To Be Used As a Key Metric in Study of “Long Hauler” COVID-19 Patients
May 25, 2022 08:00 ET
|
Daxor Corporation
Oak Ridge, TN, May 25, 2022 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, announces today participation in the National Institutes of...
Daxor Corporation to Present at the H.C. Wainwright & Company Global Investment Conference
May 12, 2022 08:00 ET
|
Daxor Corporation
NEW YORK, May 12, 2022 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, announces today that President and CEO Michael Feldschuh will...
New Data Validates Blood Volume Analysis Guided-Care, Improves Survival in Patients with Advanced Heart Failure Supported with Left Ventricular Assist Device
May 02, 2022 08:00 ET
|
Daxor Corporation
Study Presented at the International Society for Heart and Lung Transplant 42nd Annual Meeting and Scientific Sessions 2022 Oak Ridge, TN, May 02, 2022 (GLOBE NEWSWIRE) -- Daxor Corporation...
New Study from Duke Heart Demonstrates the Unique Accuracy and Utility of Daxor’s Blood Volume Diagnostic (BVA-100®) for Improving Worsening Heart Failure
April 06, 2022 08:00 ET
|
Daxor Corporation
Study Presented at the 71st Annual American College of Cardiology Meeting Oak Ridge, TN, April 06, 2022 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume...
Daxor Corporation to Participate in the Maxim Group 2022 Virtual Growth Conference
March 23, 2022 08:00 ET
|
Daxor Corporation
Oak Ridge, TN, March 23, 2022 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, announces that President and CEO Michael Feldschuh will...
Daxor Corporation CEO and President Michael Feldschuh Provides Corporate Update in Letter to Shareholders
March 01, 2022 09:00 ET
|
Daxor Corporation
Oak Ridge, TN, March 01, 2022 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today issued a corporate update in a Letter to...
Daxor Corporation Announces $1.35 Per Share NAV Increase and Files Annual Report for Fiscal 2021
March 01, 2022 08:00 ET
|
Daxor Corporation
Revenues of Operating Division Increase by 70.6% Oak Ridge, TN, March 01, 2022 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, filed...